Showing results (131-140 of 138) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 138 results.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
JAMA Surgery|April 6, 2022
Efficacy of Liposomal Bupivacaine and Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Periarticular Anesthetic for Patients Undergoing Knee Replacement: A Randomized Clinical TrialThomas W Hamilton, Ruth Knight, Jamie R Stokes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerMarc Peeters, Timothy Jay Price, Andrés Cervantes, et al.
The Journal of Allergy and Clinical Immunology|July 26, 2021
The maternal gut microbiome during pregnancy and offspring allergy and asthmaYuan Gao, Ralph Nanan, Laurence Macia, et al.
Clinical Colorectal Cancer|September 13, 2023
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal CancerDi Maria Jiang, Shruti Parshad, Luna Zhan, et al.
Vaccine|April 23, 2003
Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative studyGeoffrey J Gorse, Theresa Z O'Connor, Stephen L Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal CancerMarc Peeters, Kelly S Oliner, Timothy J Price, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGuy A van Hazel, Volker Heinemann, Navesh K Sharma, et al.
Pageof 14